• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Antiviral therapy, HBsAg seroclearance and late recurrence of hepatitis B-related hepatocellular carcinoma.

作者信息

Liu Si-Yu, Yuan Chen, Tong Xiang-Min

机构信息

Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine of Zhejiang Province, Cancer Center, Affiliated People's Hospital of Hangzhou Medical College, Zhejiang Provincial People's Hospital, Zhejiang, China; The Key Laboratory of Imaging Diagnosis and Minimally Invasive Interventional Research of Zhejiang Province, Zhejiang University Lishui Hospital, Zhejiang, China.

Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine of Zhejiang Province, Cancer Center, Affiliated People's Hospital of Hangzhou Medical College, Zhejiang Provincial People's Hospital, Zhejiang, China.

出版信息

J Hepatol. 2022 Nov;77(5):1471-1472. doi: 10.1016/j.jhep.2022.07.005. Epub 2022 Jul 19.

DOI:10.1016/j.jhep.2022.07.005
PMID:35863489
Abstract
摘要

相似文献

1
Antiviral therapy, HBsAg seroclearance and late recurrence of hepatitis B-related hepatocellular carcinoma.抗病毒治疗、乙肝表面抗原血清清除及乙肝相关肝细胞癌的晚期复发
J Hepatol. 2022 Nov;77(5):1471-1472. doi: 10.1016/j.jhep.2022.07.005. Epub 2022 Jul 19.
2
Reply to: Correspondence on "Impact of HBsAg seroclearance on late recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection".回复：关于“乙肝表面抗原血清学清除对手术切除后乙肝病毒相关肝细胞癌晚期复发的影响”的通信
J Hepatol. 2022 Nov;77(5):1472-1474. doi: 10.1016/j.jhep.2022.07.032. Epub 2022 Aug 18.
3
Long-term outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B e-antigen seroclearance.乙肝 e 抗原血清学转换后乙型肝炎表面抗原血清学清除患者的肝细胞癌和长期结局及预测评分。
Hepatology. 2018 Aug;68(2):462-472. doi: 10.1002/hep.29874. Epub 2018 Jun 6.
4
Impact of HBsAg seroclearance on late recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection.HBsAg 血清学清除对乙型肝炎病毒相关肝细胞癌切除术后晚期复发的影响。
J Hepatol. 2022 Oct;77(4):939-946. doi: 10.1016/j.jhep.2022.05.014. Epub 2022 May 26.
5
[Effect of chronic hepatitis B virus DNA negative transformation and HBsAg clearance on the occurrence of hepatocellular carcinoma].[慢性乙型肝炎病毒DNA转阴及HBsAg清除对肝细胞癌发生的影响]
Zhonghua Gan Zang Bing Za Zhi. 2019 Nov 20;27(11):831-833. doi: 10.3760/cma.j.issn.1007-3418.2019.11.004.
6
HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues.HBsAg 血清学清除在核苷（酸）类似物实现完全病毒抑制后进一步降低肝细胞癌风险。
J Hepatol. 2019 Mar;70(3):361-370. doi: 10.1016/j.jhep.2018.10.014. Epub 2018 Oct 25.
7
Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naïve chronic hepatitis B patients in Japan.日本核苷（酸）类似物初治慢性乙型肝炎患者恩替卡韦治疗的长期结局。
J Gastroenterol. 2019 Feb;54(2):182-193. doi: 10.1007/s00535-018-1502-y. Epub 2018 Aug 22.
8
HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability.核苷类似物治疗慢性乙型肝炎患者的 HBsAg 血清学清除：临床结局和持久性。
Gut. 2014 Aug;63(8):1325-32. doi: 10.1136/gutjnl-2013-305517. Epub 2013 Oct 25.
9
A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: Has the correct patient cohort been targeted?
J Hepatol. 2023 Oct;79(4):e154-e155. doi: 10.1016/j.jhep.2023.01.021. Epub 2023 Feb 1.
10
Durability of Interferon-induced Hepatitis B Surface Antigen Seroclearance.干扰素诱导的乙肝表面抗原血清清除的持久性。
Clin Gastroenterol Hepatol. 2020 Feb;18(2):514-516.e2. doi: 10.1016/j.cgh.2019.04.020. Epub 2019 Apr 10.

引用本文的文献

1
Hepatocellular carcinoma in HBsAg seroclearance: clinical features, recurrence, and prognosis following curative hepatectomy.乙肝表面抗原血清学清除后的肝细胞癌：根治性肝切除术后的临床特征、复发及预后
Ther Adv Med Oncol. 2024 Oct 18;16:17588359241289202. doi: 10.1177/17588359241289202. eCollection 2024.
2
may serve as a predictive marker for the efficacy of lenvatinib in patients with HBV-related early-stage hepatocellular carcinoma following partial hepatectomy: a retrospective cohort study.可作为肝部分切除术后乙肝相关早期肝细胞癌患者使用乐伐替尼疗效的预测标志物：一项回顾性队列研究
J Gastrointest Oncol. 2023 Dec 31;14(6):2479-2499. doi: 10.21037/jgo-23-942. Epub 2023 Dec 27.